Skip to main content
. Author manuscript; available in PMC: 2011 Sep 3.
Published in final edited form as: Cell. 2010 Sep 3;142(5):699–713. doi: 10.1016/j.cell.2010.07.044

Figure 5. Combination Therapy with Anti-CD47 Antibody and Rituximab Eliminates Lymphoma in Primary Human NHL Xenotransplant Mouse Models.

Figure 5

(A,B) Sublethally-irradiated NSG mice were transplanted intravenously with cells from a primary DLBCL patient (NHL7) and treated with the indicated antibodies. Flow cytometry of human lymphoma engraftment in the bone marrow of two representative mice is shown pre- and 14 days post-antibody treatment in (A). Data from all mice is included in (B). **p<0.01, comparing pre- and post-treatment values for each respective antibody treatment. (C) Kaplan-Meier survival analysis (Table S3) of DLBCL-engrafted mice from each antibody treatment cohort is shown (n≥10 per antibody group), with p-values calculated comparing control IgG to combination antibody treatment or anti-CD47 antibody/rituximab single antibody to combination treatment. Arrows indicate start (day 14) and stop (day 28) of treatment. (D-E) Mice engrafted intravenously with a primary FL patient sample (NHL31) were treated with a single dose of the indicated antibodies. Compared to IgG control and rituximab, anti-CD47 antibody alone or in combination with rituximab eliminated tumor burden in the peripheral blood (p=0.04, 2-way ANOVA), and bone marrow (p<0.001, t-test). (E) Lyphoma engraftment in the bone marrow was determined 14 days post-treatment. Each antibody treatment group consisted of 3 mice. For mice reported in panels D and E, human lymphoma chimerism was between 5-25% in the peripheral blood and bone marrow. See also Figure S5 and Table S3.